TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25567150

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 48

Group type: COMPARATOR
Intervention: Olmetec
Number of subjects: 48
Study: 21912072

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 19358717

Group type: EXPERIMENTAL
Intervention: Stents for percutaneous coronary interventions
Number of subjects: 132
Study: 17449579

Group type: EXPERIMENTAL
Intervention: Vitamins (folate 1 mg, vitamin B‐12 500 microg, vitamin B‐6 10 mg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 15200744

Group type: EXPERIMENTAL
Intervention: Joint Lavage (JL)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Joint Lavage plus Corticoids (JLC)
Number of subjects: 205
Study: 12370452

Group type: EXPERIMENTAL
Intervention: Presence of two or more gadolinium-enhancing lesions
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Barkhof criteria
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Combined CDMS/MRI outcomes
Number of subjects: 190
Study: 8083788

Group type: COMPARATOR
Intervention: Saline group, irrigation with 2 cc of physiologic saline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tetracycline group, irrigation with 2 cc of aqueous tetracycline hydrochloride, 50 mg/ml (5%)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Chlorhexidine group, irrigation with 2 cc 0.12% chlorhexidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group, no irrigation
Number of subjects: 7
Study: 2686071

Group type: EXPERIMENTAL
Intervention: Nifedipine (NF) administered regularly for 2 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine (NF) withdrawal after 2 months of administration
Number of subjects: 15
Study: 1097611

Group type: EXPERIMENTAL
Intervention: Carisoprodol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31430755

Group type: COMPARATOR
Intervention: CBT (Cognitive Behaviour Therapy)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: ENCERT (CBT complemented with emotion regulation training)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: ENCERT
Number of subjects: 255
Study: 29197203

Group type: EXPERIMENTAL
Intervention: Prescribed physical activity (45 minutes, four times per week for 12 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prescribed physical activity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no prescribed physical activity)
Number of subjects: 80
Study: 25885323

Group type: EXPERIMENTAL
Intervention: Multi-components school-based and family-involved scheme conducted for 9 months
Number of subjects: 70000

Group type: COMPARATOR
Intervention: Usual health practice (Control)
Number of subjects: 70000
Study: 24070130

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular transplantation of human neural stem/progenitor cells (NS/PCs) and rehabilitation training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 52
Study: 20045584

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 19030784

Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (MERCI)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (Multi MERCI)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intraarterial thrombolysis (PROACT II control)
Number of subjects: 149
Study: 16938144

Group type: EXPERIMENTAL
Intervention: Extended cognitive behaviour therapy (CBT) with or without behaviour strategies
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Brief introductory CBT
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Longer programs
Number of subjects: 2794
Study: 15340532

Group type: EXPERIMENTAL
Intervention: Sequential antiviral group (thymosin alpha1 1.6 mg, subcutaneous injection, 2 times/week for 8 weeks; interferon 500 MU, muscle injection, every other day for 6 months; lamivudine 100 mg/day after HBeAg seroconversion or interferon withdrawal for more than 18 months)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination group (interferon and thymosin alpha1 simultaneously for 6 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Lamivudine group (more than 18 months treatment with lamivudine)
Number of subjects: 74
Study: 11589607

Group type: EXPERIMENTAL
Intervention: Combined general anaesthesia and epidural analgesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 50
Study: 9598254

Group type: EXPERIMENTAL
Intervention: 0.3 mg.kg‐1 mivacurium
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-opioid anaesthesia
Number of subjects: 180

Group type: COMPARATOR
Intervention: Nitrous oxide-halothane anaesthesia
Number of subjects: 180
Study: 7834990

Group type: COMPARATOR
Intervention: Angiotensin II infusion at 10 ng min‐1 kg‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Angiotensin II infusion at 2 ng min‐1 kg‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Angiotensin II infusion at 5 ng min‐1 kg‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: D‐aldosterone infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Number of subjects: 10
Study: 3165298

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) administered three times a week at doses of 2 or 5 X 10(6) IU/m2 for chronic phase patients; 5 X 10(6) IU/m2 for accelerated phase patients.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Daily administration of Interferon alpha-2b (IFN alpha-2b) at doses from 2 to 5 X 10(6) IU/m2.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) for more than 3 months.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) in chronic phase patients.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) treatment.
Number of subjects: 82
Study: 29691840

Group type: EXPERIMENTAL
Intervention: Vascular screening
Number of subjects: 50156

Group type: COMPARATOR
Intervention: Usual care (no screening)
Number of subjects: 50156
Study: 25689546

Group type: EXPERIMENTAL
Intervention: Impella 2.5 (IR2.5)
Number of subjects: 325
Study: 23485864

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GHRH pulses/saline
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined GHRH pulses/GHRP-2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Saline pulses/GHRP-2 drive
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Saline/GHRP-2 infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Triple stimulus preceded by GHRH/GHRP-2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 26
Study: 21428766

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 18061658

Group type: EXPERIMENTAL
Intervention: Regular mail
Number of subjects: 94

Group type: COMPARATOR
Intervention: Choice of regular mail, computer telephony, or e-mail
Number of subjects: 94

Group type: COMPARATOR
Intervention: Computer telephony
Number of subjects: 94

Group type: COMPARATOR
Intervention: Regular mail vs. computer telephony
Number of subjects: 94
Study: 16435002

Group type: EXPERIMENTAL
Intervention: Cheddar cheese added to baked potato
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cheddar cheese added to pasta
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cheddar cheese added to toast
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Various toppings (including chilli con carne, baked beans, and tuna) added to baked potato
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Various toppings (including chilli con carne, baked beans, and tuna) added to pasta
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Various toppings (including chilli con carne, baked beans, and tuna) added to toast
Number of subjects: 40
Study: 12946084

Group type: EXPERIMENTAL
Intervention: High frequency rTMS (15 Hz)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (1 Hz)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 10839492

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy, concomitant chemotherapy, or radiotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 9324434

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional support
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Postoperative nutritional support
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Infusion of D5W
Number of subjects: 28
Study: 7706596

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT) diet for 30 days
Number of subjects: 5

Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT) diet for 30 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT) diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT) diet
Number of subjects: 5
Study: 3661961

Group type: EXPERIMENTAL
Intervention: Sorenson Receptal Device (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Homologous blood transfusion (Group H)
Number of subjects: 50
Study: 29321125

Group type: EXPERIMENTAL
Intervention: Web-based safety decision aid (isafe)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control website (standard, nonindividualized information)
Number of subjects: 412
Study: 27591395

Group type: EXPERIMENTAL
Intervention: Perturbation treadmill training (n=19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 39
Study: 24615132

Group type: EXPERIMENTAL
Intervention: Mass azithromycin treatment (once-treated communities)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mass azithromycin treatment (twice-treated communities)
Number of subjects: 24
Study: 23871267

Group type: EXPERIMENTAL
Intervention: Preoperative OPG tertiles (low, medium, high)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Preoperative OPG levels
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: OPG levels
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Longitudinal LV systolic function
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Markers of filling pressure
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class III or IV
Number of subjects: 124
Study: 21186648

Group type: EXPERIMENTAL
Intervention: Alternating magnetic field treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17765234

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 16

Group type: COMPARATOR
Intervention: leuprolide acetate
Number of subjects: 16
Study: 16641573

Group type: EXPERIMENTAL
Intervention: HAMS-ORS (50g/L)
Number of subjects: 183

Group type: COMPARATOR
Intervention: G-ORS (control)
Number of subjects: 183
Study: 12962750

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) with Cyclosporine (CyA) elimination at 3 months posttransplant
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cyclosporine (CyA) + Sirolimus (SRL)
Number of subjects: 57
Study: 10885415

Group type: EXPERIMENTAL
Intervention: Breathe Right (BR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8627205

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aerosol (25, 50, or 100 mg bid for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1575223

Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure less than 30 mm Hg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure between 30 and 39 mm Hg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure between 40 and 49 mm Hg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure between 50 and 59 mm Hg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure more than 60 mm Hg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: High preoperative intraocular pressure
Number of subjects: 162
Study: 3898416

Group type: EXPERIMENTAL
Intervention: Combined steroid and beta-stimulant preparation (salbutamol 100 micrograms/puff and beclomethasone dipropionate 50 micrograms/puff)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol alone (200 micrograms)
Number of subjects: 0
Study: 30098982

Group type: EXPERIMENTAL
Intervention: Prior local treatment
Number of subjects: 0
Study: 27528063

Group type: EXPERIMENTAL
Intervention: Dietary flaxseed
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Plasma oxylipins
Number of subjects: 62
Study: 24485587

Group type: EXPERIMENTAL
Intervention: d-Cycloserine (50mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23009891

Group type: EXPERIMENTAL
Intervention: 0.5-mg ranibizumab monthly injections
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: 0.3-mg ranibizumab monthly injections
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1126

Group type: COMPARATOR
Intervention: PDT (verteporfin photodynamic therapy)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 1126
Study: 20535923

Group type: EXPERIMENTAL
Intervention: Low dose BVC (0.5 mg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High dose BVC (1.0 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 36
Study: 18006170

Group type: EXPERIMENTAL
Intervention: 14-month progressive resistance training (PRT) program (initial 2-month supervised, followed by 12-month maintenance)
Number of subjects: 28
Study: 15705234

Group type: EXPERIMENTAL
Intervention: 15 g/d wolfberry (estimated to contain almost 3 mg zeaxanthin) for 28 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: No wolfberry (control group)
Number of subjects: 27
Study: 12849768

Group type: EXPERIMENTAL
Intervention: Subjects with MSA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects with MSA after initiation of the vertical lifting drive
Number of subjects: 0
Study: 10534967

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) oxycodone (administered every 12 hours)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Immediate-release (IR) oxycodone (4 times a day)
Number of subjects: 105
Study: 9345434

Group type: EXPERIMENTAL
Intervention: HTLV‐I synthetic peptide-stimulated peripheral blood lymphocytes (PBL) assay
Number of subjects: 20
Study: 1675763

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (400 mg per kilogram of body weight) every 28 days
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo (0.1 percent albumin) every 28 days
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 7148732

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sweet acidophilus milk
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2% milk, whole milk, skim milk, buttermilk
Number of subjects: 10
Study: 30465314

Group type: EXPERIMENTAL
Intervention: Implementation sites with patient-reported outcomes and weight services
Number of subjects: 801

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 801
Study: 28457217

Group type: EXPERIMENTAL
Intervention: Patients with recurrent sialadenitis
Number of subjects: 40
Study: 26842360

Group type: EXPERIMENTAL
Intervention: Combined microfinance and health leadership intervention for a period of two years.
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Delayed intervention (control arm).
Number of subjects: 1258
Study: 24556982

Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC) for the first 24 hours, initiated between 30 minutes and 1 hour after birth.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional care for the first 48 hours without SSC.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC) for the first 24 hours.
Number of subjects: 100
Study: 22383996

Group type: EXPERIMENTAL
Intervention: Cocoa+hazelnuts+phytosterols (2 g/d)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cocoa+hazelnuts+phytosterols+soluble fiber (20 g/d)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cocoa cream (control)
Number of subjects: 113
Study: 19384121

Group type: EXPERIMENTAL
Intervention: Concurrent vaginal dinoprostone (3 mg pessary) and oxytocin infusion
Number of subjects: 114

Group type: COMPARATOR
Intervention: Oxytocin infusion only (placebo)
Number of subjects: 114
Study: 17463140

Group type: EXPERIMENTAL
Intervention: LCT treatment group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 15047786

Group type: EXPERIMENTAL
Intervention: Experience Corps program for older volunteers
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study: 12506596

Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2% propofol
Number of subjects: 75
Study: 9576405

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy for 6 months with targeted INR of 2.0 to 2.85
Number of subjects: 623

Group type: COMPARATOR
Intervention: Anticoagulation therapy for 6 months
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy for 6 months or indefinitely
Number of subjects: 623

Group type: COMPARATOR
Intervention: No anticoagulation therapy during the follow-up period
Number of subjects: 623
Study: 7713766

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with 3 cycles of carboplatin/5-fluorouracil prior to surgery and radiotherapy (arm A)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard treatment with surgery and radiotherapy (arm B)
Number of subjects: 97
Study: 2105793

Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pituitary suppression with buserelin followed by pure follicle stimulating hormone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Successful pregnancies
Number of subjects: 42
Study: 346430

Group type: EXPERIMENTAL
Intervention: Cimetidine (1.6 g per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30955400

Group type: EXPERIMENTAL
Intervention: lunasin-enriched soy extract (335mg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30517599

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 9296

Group type: COMPARATOR
Intervention: Functional Activity Questionnaire (FAQ)
Number of subjects: 9296

Group type: EXPERIMENTAL
Intervention: MoCA scores <21 or <22 (depending on education)
Number of subjects: 9296
Study: 27384496

Group type: EXPERIMENTAL
Intervention: Bright Bodies (intensive family-based obesity lifestyle intervention)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Clinic Care (routine outpatient Clinic Care)
Number of subjects: 75
Study: 24670844

Group type: EXPERIMENTAL
Intervention: Sphincter-sparing surgery (SSS)
Number of subjects: 987

Group type: COMPARATOR
Intervention: Abdominoperineal resection (APR)
Number of subjects: 987
Study: 23663795

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with a load of 40% of maximal inspiratory pressure, 5 sets of 10 breaths, twice a day, 7 days a week.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 92
Study: 21779873

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 3007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3007
Study: 18834309

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study: 17592683

Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 16395633

Group type: EXPERIMENTAL
Intervention: Low-fruit energy-restricted diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-fruit energy-restricted diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 15
Study: 12518493

Group type: EXPERIMENTAL
Intervention: Experimental prototype powered toothbrush (Crest SpinBrush Pro)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Commercially available powered toothbrush (Crest SpinBrush)
Number of subjects: 70
Study: 9805693

Group type: COMPARATOR
Intervention: Isoflurane group (n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sevoflurane group (n = 13)
Number of subjects: 26
Study: 8087515

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (vindesine, cyclophosphamide, cisplatin, and lomustine) with a radiation dose of 65 Gy
Number of subjects: 353

Group type: COMPARATOR
Intervention: Radiotherapy alone with a radiation dose of 65 Gy
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy
Number of subjects: 353

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 353
Study: 2790539

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1) at 1 mg/kg for 14 days then weekly for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1)
Number of subjects: 15
Study: 4633061

Group type: EXPERIMENTAL
Intervention: Twice-weekly oral regimen of isoniazid plus PAS
Number of subjects: 247

Group type: COMPARATOR
Intervention: Daily oral regimen of isoniazid plus PAS
Number of subjects: 247
Study: 29172212

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 80 mg per day until the day of surgery (group 1)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Aspirin (ASA) stopped 4 days before surgery (group 2)
Number of subjects: 206